The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Fc‐fusion proteins: new developments and future perspectives
Open accessAbstract
Since the first description in 1989 of CD4-Fc-fusion antagonists that inhibit human immune deficiency virus entry into T cells, Fc-fusion proteins have been intensely investigated for their effectiveness to curb a range of pathologies, with several notable recent successes coming to market. These promising outcomes have stimulated the development of novel approaches to improve their efficacy and safety, while also broadening their clinical remit to other uses such as vaccines and intravenous immunoglobulin therapy. This increased attention has also led to non-clinical applications of Fc-fusions, such as affinity reagents in microarray devices. Here we discuss recent results and more generally applicable strategies to improve Fc-fusion proteins for each application, with particular attention to the newer, less charted areas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mammen, M., Choi, S.-K., & Whitesides, G. M. (1998) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19981102)37:20<2754::aid-anie2754>3.0.co;2-3 · Cited by 4,110
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C., Sutthent, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113425 · Cited by 1,808
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910
Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Théry, C., Rescigno, M., Saito, T., Verbeek, S., Bonnerot, C., Ricciardi-Castagnoli, P., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.371 · Cited by 898
Transmembrane TNF- : structure, function and interaction with anti-TNF agents
Horiuchi, T., Mitoma, H., Harashima, S.-I., Tsukamoto, H., & Shimoda, T. (2010) · Rheumatology · doi:10.1093/rheumatology/keq031 · Cited by 864
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 2×
“…ability of IgG is consistent with the observation that decreased sialylation and galactosylation of IgG are observed in patients with arthritis (Jefferis, 2009), and modifications to the carbohydrate content of IgG have been posited as a molecular explanation for the ‘hygiene-hypothesis’…”
Rituximab: Mechanism of Action
Weiner, G. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.011 · Cited by 786
Van den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.-Y., Shealy, D., & Wagner, C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.418 · Cited by 672
Enhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 653
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall'Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 646
Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway
Anthony, R. M., Kobayashi, T., Wermeling, F., & Ravetch, J. V. (2011) · Nature · doi:10.1038/nature10134 · Cited by 633
Designing CD4 immunoadhesins for AIDS therapy
Capon, D. J., Chamow, S. M., Mordenti, J., Marsters, S. A., Gregory, T., Mitsuya, H., Byrn, R. A., Lucas, C., Wurm, F. M., Groopman, J. E., et al. (1989) · Nature · doi:10.1038/337525a0 · Cited by 615
Hoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577
Strategies for extended serum half-life of protein therapeutics
Kontermann, R. E. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.012 · Cited by 573
Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly
Saad, J. S., Miller, J., Tai, J., Kim, A., Ghanam, R. H., & Summers, M. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602818103 · Cited by 545
Metabolic properties of IgG subclasses in man
Morell, A., Terry, W. D., & Waldmann, T. A. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106279 · Cited by 526
Introduction to current and future protein therapeutics: A protein engineering perspective
Carter, P. J. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.02.013 · Cited by 467
Antibody fragments: Hope and hype
Nelson, A. L. (2010) · mAbs · doi:10.4161/mabs.2.1.10786 · Cited by 463
Human antibody–Fc receptor interactions illuminated by crystal structures
Woof, J. M., & Burton, D. R. (2004) · Nature Reviews Immunology · doi:10.1038/nri1266 · Cited by 387
Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., & Yamaguchi, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903296 · Cited by 368
Gaboriaud, C., Juanhuix, J., Gruez, A., Lacroix, M., Darnault, C., Pignol, D., Verger, D., Fontecilla-Camps, J. C., & Arlaud, G. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307764200 · Cited by 362
Daëron, M., Malbec, O., Latour, S., Arock, M., & Fridman, W. H. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117701 · Cited by 360
Entry of herpesviruses into mammalian cells
Heldwein, E. E., & Krummenacher, C. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7570-z · Cited by 355
Li, F., & Ravetch, J. V. (2011) · Science · doi:10.1126/science.1206954 · Cited by 335
Zhu, X., Meng, G., Dickinson, B. L., Li, X., Mizoguchi, E., Miao, L., Wang, Y., Robert, C., Wu, B., Smith, P. D., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.3266 · Cited by 322
Peppel, K., Crawford, D., & Beutler, B. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.6.1483 · Cited by 321
Mouse model recapitulating human Fcγ receptor structural and functional diversity
Smith, P., DiLillo, D. J., Bournazos, S., Li, F., & Ravetch, J. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203954109 · Cited by 307
Development trends for therapeutic antibody fragments
Nelson, A. L., & Reichert, J. M. (2009) · Nature Biotechnology · doi:10.1038/nbt0409-331 · Cited by 305
Unmet needs in modern vaccinology
Leroux-Roels, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.021 · Cited by 304
Antibody therapeutics: isotype and glycoform selection
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294
Engineered Antibodies with Increased Activity to Recruit Complement
Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291
Stapleton, N. M., Andersen, J. T., Stemerding, A. M., Bjarnarson, S. P., Verheul, R. C., Gerritsen, J., Zhao, Y., Kleijer, M., Sandlie, I., de Haas, M., et al. (2011) · Nature Communications · doi:10.1038/ncomms1608 · Cited by 286
Gonzalez, L. C., Loyet, K. M., Calemine-Fenaux, J., Chauhan, V., Wranik, B., Ouyang, W., & Eaton, D. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409071102 · Cited by 252
Isotype selection in antibody engineering
Salfeld, J. G. (2007) · Nature Biotechnology · doi:10.1038/nbt1207-1369 · Cited by 239
Yeung, Y. A., Leabman, M. K., Marvin, J. S., Qiu, J., Adams, C. W., Lien, S., Starovasnik, M. A., & Lowman, H. B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804182 · Cited by 237
Antibody-based therapeutics to watch in 2011
Reichert, J. M. (2011) · mAbs · doi:10.4161/mabs.3.1.13895 · Cited by 236
Bitonti, A. J., Dumont, J. A., Low, S. C., Peters, R. T., Kropp, K. E., Palombella, V. J., Stattel, J. M., Lu, Y., Tan, C. A., Song, J. J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403235101 · Cited by 233
Wojtowicz, W. M., Wu, W., Andre, I., Qian, B., Baker, D., & Zipursky, S. L. (2007) · Cell · doi:10.1016/j.cell.2007.08.026 · Cited by 222
Baker, K., Qiao, S.-W., Kuo, T. T., Aveson, V. G., Platzer, B., Andersen, J.-T., Sandlie, I., Chen, Z., de Haar, C., Lencer, W. I., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019037108 · Cited by 216
Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses
Stäger, S., Alexander, J., Kirby, A. C., Botto, M., Rooijen, N. V., Smith, D. F., Brombacher, F., & Kaye, P. M. (2003) · Nature Medicine · doi:10.1038/nm933 · Cited by 213
Treon, S. P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R., & Anderson, K. C. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200105000-00011 · Cited by 205
Davis, J. H., Aperlo, C., Li, Y., Kurosawa, E., Lan, Y., Lo, K.-M., & Huston, J. S. (2010) · Protein Engineering, Design and Selection · doi:10.1093/protein/gzp094 · Cited by 194
A Novel Human IgA Monoclonal Antibody Protects against Tuberculosis
Balu, S., Reljic, R., Lewis, M. J., Pleass, R. J., McIntosh, R., van Kooten, C., van Egmond, M., Challacombe, S., Woof, J. M., & Ivanyi, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003189 · Cited by 184
Self-citationThe human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity
Bakema, J. E., & van Egmond, M. (2011) · Mucosal Immunology · doi:10.1038/mi.2011.36 · Cited by 182
The netrin-G1 ligand NGL-1 promotes the outgrowth of thalamocortical axons
Lin, J. C., Ho, W.-H., Gurney, A., & Rosenthal, A. (2003) · Nature Neuroscience · doi:10.1038/nn1148 · Cited by 182
Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies
Beck, A., & Reichert, J. M. (2011) · mAbs · doi:10.4161/mabs.3.5.17334 · Cited by 179
Synthetic therapeutic antibodies
Sidhu, S. S., & Fellouse, F. A. (2006) · Nature Chemical Biology · doi:10.1038/nchembio843 · Cited by 170
Optimization of Fc-mediated effector functions of monoclonal antibodies
Strohl, W. R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.011 · Cited by 168
Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology
Huang, C. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.010 · Cited by 166
Kardava, L., Moir, S. L., Wang, W., Ho, J., Buckner, C. M., Posada, J. G., O’Shea, M. A., Roby, G. A., Chen, J., Sohn, H. W., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45685 · Cited by 166
Natural IgM in Immune Equilibrium and Harnessing Their Therapeutic Potential
Kaveri, S. V., Silverman, G. J., & Bayry, J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102107 · Cited by 163
Efficient mucosal vaccination mediated by the neonatal Fc receptor
Ye, L., Zeng, R., Bai, Y., Roopenian, D. C., & Zhu, X. (2011) · Nature Biotechnology · doi:10.1038/nbt.1742 · Cited by 159
Non-immunoglobulin based protein scaffolds
Löfblom, J., Frejd, F. Y., & Ståhl, S. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.002 · Cited by 156
IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes
Séïté, J.-F., Cornec, D., Renaudineau, Y., Youinou, P., Mageed, R. A., & Hillion, S. (2010) · Blood · doi:10.1182/blood-2009-12-261461 · Cited by 154
Polymer–drug conjugates as nano-sized medicines
Canal, F., Sanchis, J., & Vicent, M. J. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.003 · Cited by 153
Monocyte Subsets Responsible for Immunoglobulin G-Dependent Effector Functions In Vivo
Biburger, M., Aschermann, S., Schwab, I., Lux, A., Albert, H., Danzer, H., Woigk, M., Dudziak, D., & Nimmerjahn, F. (2011) · Immunity · doi:10.1016/j.immuni.2011.11.009 · Cited by 152
Carrillo‐Conde, B., Song, E.-H., Chavez-Santoscoy, A. V., Phanse, Y., Ramer‐Tait, A. E., Pohl, N. L. B., Wannemuehler, M. J., Bellaire, B. H., & Narasimhan, B. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200213r · Cited by 147
Cutting Edge: Human FcRL4 and FcRL5 Are Receptors for IgA and IgG
Wilson, T. J., Fuchs, A. G., & Colonna, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102651 · Cited by 134
Veeramani, S., Wang, S., Dahle, C. E., Blackwell, S. E., Jacobus, L., Knutson, T. M., Button, A. M., Link, B. K., & Weiner, G. J. (2011) · Blood · doi:10.1182/blood-2011-05-351411 · Cited by 132
Rapaka, R. R., Ricks, D. M., Alcorn, J. F., Chen, K., Khader, S. A., Zheng, M., Plevy, S. E., Bengtén, E., & Kolls, J. K. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100034 · Cited by 127
IVI g‐mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR 1
Schwab, I., Biburger, M., Krönke, G., Schett, G. A., & Nimmerjahn, F. (2012) · European Journal of Immunology · doi:10.1002/eji.201142260 · Cited by 113
Discovery and development of biopharmaceuticals: current issues
Strohl, W. R., & Knight, D. M. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.012 · Cited by 111
Li, L., Palaniyandi, S., Zeng, R., Bai, Y., Liu, X., Wang, Y., Pauza, C. D., Roopenian, D. C., & Zhu, X. (2011) · Journal of Virology · doi:10.1128/jvi.05441-11 · Cited by 110
IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms.
Griffiss, J. M., & Goroff, D. K. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.6.2882 · Cited by 109
Bakema, J. E., & van Egmond, M. (2011) · mAbs · doi:10.4161/mabs.3.4.16092 · Cited by 96
Getahun, A., Dahlström, J., Wernersson, S., & Heyman, B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5269 · Cited by 94
Hsu, T.-L., Cheng, S., Yang, W., Chin, S.-W., Chen, B.-H., Huang, M., Hsieh, S.-L., & Wong, C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.065961 · Cited by 93
Martin, W. L., & Björkman, P. J. (1999) · Biochemistry · doi:10.1021/bi9913505 · Cited by 90
Specific monoclonal IgM is a potent adjuvant in murine malaria vaccination
Harte, P. G., Cooke, A., & Playfair, J. H. L. (1983) · Nature · doi:10.1038/302256a0 · Cited by 89
Polymeric human Fc-fusion proteins with modified effector functions
Mekhaiel, D. N. A., Czajkowsky, D. M., Andersen, J. T., Shi, J., El-Faham, M., Doenhoff, M., McIntosh, R. S., Sandlie, I., He, J., Hu, J., et al. (2011) · Scientific Reports · doi:10.1038/srep00124 · Cited by 85
Self-citationWright, G. J. (2009) · Molecular BioSystems · doi:10.1039/b903580j · Cited by 82
Natural IgM antibodies: The orphaned molecules in immune surveillance
Vollmers, H. P., & Brändlein, S. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.08.007 · Cited by 79
Pfirsch, S., Aloulou, M., Xu, T., Claver, J., Kanamaru, Y., Tiwari, M. K., Launay, P., Monteiro, R. C., & Blank, U. (2011) · Science Signaling · doi:10.1126/scisignal.2001309 · Cited by 78
Vire, B., David, A., & Wiestner, A. U. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100532 · Cited by 75
Targeting FcαRI on Polymorphonuclear Cells Induces Tumor Cell Killing through Autophagy
Bakema, J. E., Ganzevles, S. H., Fluitsma, D. M., Schilham, M. W., Beelen, R. H. J., Valerius, T., Lohse, S., Glennie, M. J., Medema, J. P., & van Egmond, M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002581 · Cited by 75
Expression and role of Fc- and complement-receptors on human dendritic cells
Bajtay, Z., Csomor, E., Sándor, N., & Erdei, A. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.11.023 · Cited by 74
O’Reilly, M. K., Collins, B. E., Han, S., Liao, L., Rillahan, C. D., Kitov, P. I., Bundle, D. R., & Paulson, J. C. (2008) · Journal of the American Chemical Society · doi:10.1021/ja802008q · Cited by 72
Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., Stein, R., & Chang, C. (2009) · Blood · doi:10.1182/blood-2008-10-187138 · Cited by 72
Kumar, M., Hunag, Y. P., Glinka, Y., Prud’homme, G. J., & Wang, Q. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302836 · Cited by 71
Lohse, S., Derer, S., Beyer, T. D., Klausz, K., Peipp, M., Leusen, J. H. W., van de Winkel, J. G. J., Dechant, M., & Valerius, T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003082 · Cited by 67
Intracellular antibody‐mediated immunity and the role of TRIM21
McEwan, W. A., Mallery, D. L., Rhodes, D. A., Trowsdale, J., & James, L. C. (2011) · BioEssays · doi:10.1002/bies.201100093 · Cited by 67
Soltani, N., Kumar, M., Glinka, Y., Prud’homme, G. J., & Wang, Q. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302944 · Cited by 61
Neonatal FcR Overexpression Boosts Humoral Immune Response in Transgenic Mice
Cervenak, J., Bender, B., Schneider, Z., Magna, M., Carstea, B. V., Liliom, K., Erdei, A., Bösze, Z., & Kacskovıcs, I. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000353 · Cited by 61
Karagiannis, S. N., Josephs, D. H., Karagiannis, P., Gilbert, A. E., Saul, L., Rudman, S. M., Dodev, T. S., Koers, A., Blower, P. J., Corrigan, C. J., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1162-8 · Cited by 60
A secreted protein microarray platform for extracellular protein interaction discovery
Ramani, S. R., Tom, I., Lewin‐Koh, N., Wranik, B. J., DePalatis, L., Zhang, J., Eaton, D., & Gonzalez, L. C. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.09.017 · Cited by 59
Muda, M., Gross, A. W., Dawson, J., He, C., Kurosawa, E., Schweickhardt, R. L., Dugas, M., Soloviev, M., Bernhardt, A., Fischer, D., et al. (2011) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq123 · Cited by 55
How antibodies act as natural adjuvants
Getahun, A., & Heyman, B. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.11.005 · Cited by 54
Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
Wang, Q., Chen, K., Liu, R., Zhao, F., Gupta, S., Zhang, N., & Prud’homme, G. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012734 · Cited by 52
IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines.
Reali, E., Greiner, J. W., Corti, A., Gould, H. J., Bottazzoli, F., Paganelli, G., Schlom, J., & Siccardi, A. G. (2001) · PubMed · Cited by 50
The influence of the hinge region length in binding of human IgG to human Fcγ receptors
Redpath, S., Michaelsen, T. E., Sandlie, I., & Clark, M. (1998) · Human Immunology · doi:10.1016/s0198-8859(98)00075-5 · Cited by 48
Effector mechanisms of therapeutic antibodies against ErbB receptors
Peipp, M., Dechant, M., & Valerius, T. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.012 · Cited by 48
CD22 serves as a receptor for soluble IgM
Adachi, T., Harumiya, S., Takematsu, H., Kozutsumi, Y., Wabl, M. R., Fujimoto, M., & Tedder, T. F. (2011) · European Journal of Immunology · doi:10.1002/eji.201141899 · Cited by 45
IgM, FcμRs, and Malarial Immune Evasion
Czajkowsky, D. M., Salanti, A., Ditlev, S. B., Shao, Z., Ghumra, A., Rowe, J. A., & Pleass, R. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000203 · Cited by 43
Self-citationSantiago, T., Викторович, К. С., Reshetnikova, E. S., Chikaev, N. A., Volkova, O. Y., Мечетина, Л. В., Zhao, M., Davis, R. S., Taranin, A. V., Najakshin, A. M., et al. (2010) · International Immunology · doi:10.1093/intimm/dxq456 · Cited by 40
Wilson, T. J., Gilfillan, S., & Colonna, M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001428 · Cited by 38
Congy‐Jolivet, N., Probst, A., Watier, H., & Thibault, G. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.06.013 · Cited by 37
Shoji-Hosaka, E., Kobayashi, Y., Wakitani, M., Uchida, K., Niwa, R., Nakamura, K., & Shitara, K. (2006) · The Journal of Biochemistry · doi:10.1093/jb/mvj207 · Cited by 34
Saxon, A., Kepley, C. L., & Zhang, K. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.10.017 · Cited by 31
Single-Chain Fv-Based Anti-HIV Proteins: Potential and Limitations
West, A. P., Galimidi, R. P., Gnanapragasam, P. N. P., & Björkman, P. J. (2011) · Journal of Virology · doi:10.1128/jvi.05848-11 · Cited by 31
Soluble Fc Fusion Proteins for Biomedical Research
Flanagan, M. L., Arias, R. S., Hu, P., Khawli, L. A., & Epstein, A. L. (2007) · Methods in molecular biology · doi:10.1007/978-1-59745-323-3_3 · Cited by 25
Shi, J., McIntosh, R. S., Adame-Gallegos, J. R., Dehal, P. K., van Egmond, M., van de Winkel, J. G. J., Draper, S. J., Forbes, E. K., Corran, P. H., Holder, A. A., et al. (2011) · BMC Biotechnology · doi:10.1186/1472-6750-11-77 · Cited by 22
Self-citationToll-Like Receptor 4 Decoy, TOY, Attenuates Gram-Negative Bacterial Sepsis
Jung, K., Lee, J. E., Kim, H.-Z., Kim, H. M., Park, B. S., Hwang, S.-I., Lee, J., Kim, S. C., & Koh, G. Y. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007403 · Cited by 19
Systemic administration of an Fcγ–Fcε-fusion protein in house dust mite sensitive nonhuman primates
Scott, M. R. V., Mertsching, E., Negrou, E., Miles, J. J., Stallings, H. W., Graff, C. L., & Kehry, M. R. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.05.001 · Cited by 19
A Conserved Host and Pathogen Recognition Site on Immunoglobulins: Structural and Functional Aspects
Wines, B. D., Trist, H. M., Farrugia, W., Ngo, C., Trowsdale, J., Areschoug, T., Lindahl, G., Fraser, J. D., & Ramsland, P. A. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0106-3_6 · Cited by 15
An Antitumor Cellular Vaccine Based on a Mini-Membrane IgE
Nigro, E. A., Soprana, E., Brini, A. T., Ambrosi, A., Yenagi, V., Dombrowicz, D., Siccardi, A. G., & Vangelista, L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101842 · Cited by 13
Logan, G. J., Wang, L., Zheng, M., Ginn, S. L., Coppel, R. L., & Alexander, I. E. (2008) · Gene Therapy · doi:10.1038/gt.2008.168 · Cited by 10
TNF receptor II fusion protein with tandemly repeated Fc domains
Nagashima, H., Kaneko, K., Yamanoi, A., Motoi, S., Konakahara, S., Kohroki, J., & Masuho, Y. (2011) · The Journal of Biochemistry · doi:10.1093/jb/mvq149 · Cited by 9
Do regulatory antibodies offer an alternative mechanism to explain the hygiene hypothesis?
Mekhaiel, D., Daniel‐Ribeiro, C. T., Cooper, P. J., & Pleass, R. J. (2011) · Trends in Parasitology · doi:10.1016/j.pt.2011.08.003 · Cited by 8
Self-citationA novel Fcγ receptor ligand augments humoral responses by targeting antigen to Fcγ receptors
Jensen, M. A., Arnason, B. G. W., & White, D. M. (2007) · European Journal of Immunology · doi:10.1002/eji.200636321 · Cited by 7
Detection of weak receptor–ligand interactions using I g M and J ‐chain‐based fusion proteins
Ammann, J. U., Jahnke, M., Dyson, M. R., Kaufman, J., & Trowsdale, J. (2012) · European Journal of Immunology · doi:10.1002/eji.201142151 · Cited by 6
Cited by
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Chen, B.-M., Cheng, T.-L., & Roffler, S. R. (2021) · ACS Nano · doi:10.1021/acsnano.1c05922 · Cited by 563
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
Strohl, W. R. (2015) · BioDrugs · doi:10.1007/s40259-015-0133-6 · Cited by 461
Therapeutic modulation of Notch signalling — are we there yet?
Andersson, E. R., & Lendahl, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4252 · Cited by 457
Nanotechnology for protein delivery: Overview and perspectives
Yu, M., Wu, J., Shi, J., & Farokhzad, O. C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.012 · Cited by 410
Metadata
- Authors
- Czajkowsky, D. M., Hu, J., Shao, Z., & Pleass, R. J.
- Venue
- EMBO Molecular Medicine
- Published
- 2012-07-26
- Volume
- 4
- Issue
- 10
- Pages
- 1015-1028
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2141247392
- Cited by
- 476
- References
- 115
- FWCI
- 15.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.